In male Wistar rats with mild intestinal ischemia/reperfusion injury, intravenous Repertaxin lysine salt reduced intestinal and lung vascular leakage and neutrophil accumulation in a dose-dependent manner over the reported 3–30 mg/kg range. Protection was strongest at 30 mg/kg. These were short-term pretreatment observations around reperfusion. [2]
In nude mice bearing ovarian tumors with mesenchymal stromal cells, the combination of AdooQ-supplied Reparixin and carboplatin was associated with lower tumor-associated luminescence than carboplatin alone. An added antitumor effect was absent after macrophage depletion, limiting the result to the tested stromal and immune context. The paper does not specify the Reparixin salt form or lot, and the reviewed methods do not establish matched solvent controls, limiting attribution to Reparixin alone. [3]
Reported Repertaxin lysine salt in mild intestinal reperfusion injury
Animal study · Male Wistar rats (200–220 g); mild intestinal ischemia/reperfusion, 30 min ischemia followed by 30 min reperfusion [2]
The reported salt reduced intestinal and lung vascular leakage and MPO-based neutrophil accumulation in a dose-dependent manner; the strongest reported protection was at 30 mg/kg.
Conditions shared by the study groups
- Route
- Intravenous
- Frequency
- One administration
- Treatment course
- 5 min before reperfusion (Fig. 4 caption); endpoints after 30 min reperfusion
- Vehicle
- Saline
- Repertaxin dose series
- Model: Male Wistar rats; mild intestinal I/R
- Reported limits: Exact numerical means not reported as a table and not reconstructed from bars; Fig. 4 significance-symbol/caption mismatch prevents reliable panel-wise P-value attribution.
Methods and source locations
Compound reported in the paper: Reparixin (Repertaxin); Compound label in the paper: (R)-Repertaxin L-lysine salt
Reported lysine-salt pharmacology only. No conversion of reported concentration/dose and no assumption of equivalent potency for an AdooQ lot.
Fig. 1 material caption; Animals and I/R treatment/control methods; permeability/MPO and statistics methods; mild I/R Results; Fig. 4a-d and caption
Repertaxin dose series · Fig. 1 material caption; Animals and I/R treatment/control methods; permeability/MPO and statistics methods; mild I/R Results; Fig. 4a-d and caption
Reparixin plus carboplatin in stromal-cell-associated ovarian tumor chemoresistance
Animal study · Female Swiss nude athymic mice, 4–5 weeks old on arrival; intraperitoneal SKOV-3/SKOV-3luc tumors with or without MSCs [3]
MSCs diminished the tumor response to carboplatin. The Reparixin/carboplatin combination had lower tumor-associated luminescence than carboplatin alone in the MSC-containing setting. Without a specified matched solvent control, the contribution of Reparixin cannot be fully separated from formulation differences; monotherapy efficacy is not established.
Conditions shared by the study groups
- Frequency
- Reparixin three times/week; carboplatin every 7 days
- Treatment course
- Day 7 start, 3 weeks; in-vivo imaging Day 34 and terminal tissue/lavage luminescence Day 36
- Vehicle
- Reparixin DMSO/PBS (v/v; ratio unspecified); carboplatin saline
- SKOV-3 + MSC, carboplatin + Reparixin
- Model: Female Swiss nude athymic mice, 4–5 weeks old on arrival; intraperitoneal SKOV-3/SKOV-3luc tumors with or without MSCs
- Reported limits: Reparixin/carboplatin injection routes not specified; no Reparixin-only treatment group shown in Fig. 4; no exact luminescence values reconstructed; group-specific solvent control not documented.
Methods and source locations
Compound reported in the paper: Reparixin (Repertaxin); Compound label in the paper: Reparixin (AdooQ Bioscience; form unspecified)
Mouse combination-treatment findings for the named supplier material; no specific A12383 lot, stereochemical assay or salt-form validation.
Results Implication of CXCR1/2 axis in OTC resistance to carboplatin; Fig. 4c-f and caption; Animals and In vivo experiments methods
SKOV-3 + MSC, carboplatin + Reparixin · Results Implication of CXCR1/2 axis in OTC resistance to carboplatin; Fig. 4c-f and caption; Animals and In vivo experiments methods
Macrophage depletion limits the Reparixin combination effect
Animal study · Female Swiss nude athymic mice, 4–5 weeks old on arrival; intraperitoneal SKOV-3/SKOV-3luc tumors with or without MSCs; additional clodronate-liposome depletion intervention [3]
In macrophage-depleted tumor-bearing mice, adding Reparixin to carboplatin did not produce an additional antitumor effect. This limits the inference to an MSC/macrophage-dependent context.
Conditions shared by the study groups
- Route
- Reparixin/carboplatin: not specified; clodronate liposome: intraperitoneal
- Frequency
- Reparixin three times/week; carboplatin every 7 days; clodronate once/week
- Treatment course
- Clodronate began one day before cell administration, weekly for 4 weeks; cancer treatment Day 7 for 3 weeks; terminal Day 36
- Vehicle
- Reparixin DMSO/PBS (v/v, ratio unspecified); carboplatin saline; clodronate PBS
- Macrophage-depleted combination comparison
- Model: Female Swiss nude athymic mice, 4–5 weeks old on arrival; intraperitoneal SKOV-3/SKOV-3luc tumors with or without MSCs; clodronate liposome intervention
- Reported limits: Final evaluable n not specified in Fig. S7 caption; ns does not demonstrate equivalence; depletion verification/empty-liposome controls are not established here.
Methods and source locations
Compound reported in the paper: Reparixin (Repertaxin); Compound label in the paper: Reparixin (AdooQ Bioscience; form unspecified)
Mouse combination-treatment findings for the named supplier material; no specific A12383 lot, stereochemical assay or salt-form validation.
Results macrophage-depletion paragraph preceding peritoneal cytokine results; In vivo experiments methods; Supplementary PDF p. 9, Fig. S7a,b and caption
Macrophage-depleted combination comparison · Results macrophage-depletion paragraph preceding peritoneal cytokine results; In vivo experiments methods; Supplementary PDF p. 9, Fig. S7a,b and caption